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ABSTRACT
Objectives: To describe and identify the socio-behavioral factors predicting willingness
towards deprescribing among older adults with osteoporosis.
Design, Setting, and Participants: For this population-based survey study of US
Medicare beneficiaries, data was obtained from the Medication Attitudes Module distributed to
the participants in Round 6 (2015) of the National Health and Aging Trends Study. Our study
population consisted to respondents who were diagnosed with osteoporosis in round 6 or earlier
and who responded to the Medication Attitude Module.
Main outcome and Measures: Response to the statement “I would like to reduce the
number of medicines I am taking” was the main outcome of interest. The predictor variables were
chosen based on the Health Belief Model. The predictor variables in the study included
demographic variables and other patient characteristics.
Results: Of the 555 Medicare beneficiaries included in the study, 483 were women
(88.18%, weighted) and the majority were 65-74 years old (n=149, weighted 41.66%). Most of
our cohort i.e., 336 respondents (62.86%, weighted) were receptive towards wanting to reduce the
number of medicines they are consuming. In our multivariable logistic regression model, we found
that odds of wanting to reduce the number of medications for those taking 3-10 medications
relative to those taking at least 2 medications were significantly more (OR 2.42; 95% CI,1.204.86).
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Similarly, the odds of wanting to reduce the number of medications for those taking more
than 10 medications relative to those taking at least 2 medications were also significantly higher
(OR 14.66; 95% CI, 5.36-40.11). Additionally, respondents who were 85 years and older had
significantly lower odds of wanting to reduce the number of medications relative to respondents
aged between 65 to 75 years (OR 0.45; 95% CI, 0.23-0.89).
Conclusion: The management of treatment among older adults is challenging, mainly
because the problem of polypharmacy is common among them. Healthcare providers need to take
into consideration the patient’s views regarding their treatment regimen. This study has filled an
important gap in the field of deprescribing by identifying the potential factors that may guide
willingness of patients diagnosed with osteoporosis towards deprescribing.

iii

LIST OF ABBREVIATIONS AND SYMBOLS
DXA

Dual x-ray absorptiometry

SERM

Selective estrogen receptor modulator

BMD

Bone mineral density

TCA

Tricyclic antidepressant agents

PIM

Potentially inappropriate medication

ADR

Adverse drug reaction

IP

Inappropriate Prescribing

WHO
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INTRODUCTION

Osteoporosis is a skeletal disorder which is defined as the deterioration of bone structure
and reduced bone density which further leads to increased susceptibility to fragility fractures. It is
a common disease affecting millions of Americans (Office of the Surgeon General US, 2004).
According to World Health Organization, the bone density of less than 2.5 standard deviations
below the young adult standard is characterized as osteoporosis (World Health Organization,
2004). The reduced bone strength in osteoporosis is due to the decreased bone mass, abnormal
bone quality, high bone turnover, deteriorated microarchitecture of bones and mineralization
deficits (Borges et al., 2006). Osteoporosis affects approximately 9% of older adults above 50
years (Resnick et al., 2014). The progressive aging of the world’s population results in increased
severity and frequency of osteoporosis which is a world-wide socioeconomic problem (Dontas &
Yiannakopoulos, 2007). For osteoporotic fractures, in 2002 the national direct care expenditure
ranged from $12 billion to $18 billion. These costs are projected to double or triple over the next
few years in parallel with increases in prevalence of osteoporosis and the aging of the US
population (Office of the Surgeon General US, 2004).
Osteoporosis may remain asymptomatic for many years until the first fracture occurs
hence, it is sometimes also referred to as a ‘silent disease’ (Gass & Dawson-Hughes, 2006). In the
United States, osteoporosis treatment for the 2% of hip fracture patients begins after their
hospitalization (Jennings et al., 2010). Treatment of osteoporosis is determined by the testing to
identify the patient with osteoporosis, decision to initiate the treatment and adherence to the
1

therapy once the treatment has started (Yood et al.,2008). Dual x-ray absorptiometry (DXA) is a
preferred technique by most guidelines to measure BMD (Gass, 2006).
The major goals for the osteoporosis treatment are fracture prevention; stabilization of
increased bone mass; relieving symptoms of fractures and skeletal deformity and maximizing the
physical function of an individual (Menopause Guidelines Revision Task Force, 2006). The
current therapies in United States for osteoporosis include bisphosphonates (primarily alendronate,
risedronate and ibandronate); selective estrogen receptor modulator (SERM), raloxifene,
calcitonin and teriparatide; hormone replacement therapy and some over-the-counter therapies
such as calcium and vitamin D (Badamgarav & Fitzpatrick, 2006).
One of the reasons the treatment for osteoporosis is generally not started by the physicians
is due to the issue of polypharmacy which can aggravate the problem and increase the risk of drug
interactions in the patient (Gosch et al., 2012). There has been an adequate increase in the number
of the effective drugs to treat osteoporosis. But despite that, evidence suggests that patients
diagnosed with osteoporosis are either not being offered these drugs or when prescribed not taking
them. (Eisman & White, 2019). Pain, disability, deformity, psychological distress, premature death
are some of the consequences of osteoporosis related fractures (Borges & Bilezikian, 2006).
Osteoporosis results in a decreased quality of life, disability and increased morbidity and mortality
in older people (Cummings & Melton, 2002). Patients above 60 years diagnosed with osteoporosis
are more prone to falls and might face severe consequences hence, prevention of falls should be
the priority among the older patients (Menopause Guidelines Revision Task Force, 2006). Patients
with osteoporosis should be assessed for risk factors for falls such as - previous falls, fainting or
loss of consciousness, muscle weakness, dizziness or balance problems, impaired vision, and
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certain medications (e.g., sedatives, narcotic analgesics, anticholinergics, and antihypertensives)
(Borges, 2006).
Patient adherence rate with osteoporosis medications is approximately 60%, whereas the
discontinuation rates for the osteoporosis medication are high during the first year of the therapy
(Badamgarav & Fitzpatrick, 2006). The adherence rate with medications like bisphosphonates and
raloxifene is around 55% to 65%. These drugs have the capability to increase the bone mineral
density (BMD) and simultaneously decrease the risk of fracture. Adherence to medications may
be influenced by the factors such as type and stage of disease, cost, frequency and complexity of
the dosing regimen, medication adverse effects, age, mental state, acceptance and understanding
of the illness, and in the case of osteoporosis specifically, BMD testing and prior fracture
(Badamgarav, 2006).
Osteoporosis therapy has its own set of side effects associated with it. One of the sideeffects the estrogen therapy can have is the increase in cardiovascular events and the breast cancer
risk in women undergoing estrogen therapy (Khosla & Hofbauer, 2017). Consumption of Selective
estrogen receptor modulators (SERM) like raloxifene can cause instances of hot flashes and venous
thromboembolism. Uptake of bisphosphonates can result in rare side effects such as atypical femur
fractures and osteonecrosis of jaw. Although the side effect of osteonecrosis is limited to the use
of bisphosphonates, the patient perceptions and concerns about these risks has been extending to
all classes of osteoporosis drugs (Eisman & White, 2019). This is one of the reasons why patients
with osteoporosis are dismissing the osteoporosis medication and deciding to “take their chances”
with fractures (Khosla & Shane, 2016). It has been observed that the desire of a patient to end an
anti-resorptive therapy is largely driven by the anxiety about the potential side effects such as
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osteonecrosis of the jaws or the atypical femur fractures which can occur due to the therapy
(Eisman, 2019).
Currently, elderly patients more than 75 years take at least eight different drugs on average
(Gosch et al., 2012). There is a high prevalence of polypharmacy among patients with
osteoporosis, especially in the geriatric population where comorbidities are commonly present. A
correlation has been observed between polypharmacy and undertreatment among patients with
osteoporosis (Gosch et al., 2012). The use of multiple medications can be useful for some older
adults having multiple diseases, but it may result in the increased risk of adverse drug events,
hospitalizations, falls, mortality, and other negative outcomes in older adults. Preexisting
polypharmacy can have negative outcome in the osteoporosis therapy as well (Gosch et al., 2012).
For example, a patient who is already on a glucocorticoid therapy, tricyclic antidepressant agents
(TCA), Thiazolidinedione, or antiepileptic agents can experience an increased risk of fracture or
fall depending on the dosage administered. Vitamin K or chemotherapeutics can also have negative
effects on bone metabolism. Long term use of Proton pump inhibitors can lead to higher risk of
vertebral and peripheral fractures (Gosch, 2012). A polypharmacy reduction trial in older people
utilizing the palliative – geriatric practice algorithm showed that over half of the medicines can be
discontinued (Gnjidic et al., 2012). Hence, deprescribing is often advised when there is a high risk
of potential adverse events due to the patient being on multiple therapies.
The term deprescribing means a physician-supervised process of discontinuation of an
inappropriate medication a patient might be consuming. The goal of deprescribing is to minimize
the risks associated with inappropriate medications, thereby improving the quality-of-life
outcomes (Reeve et al., 2018). A majority of older adults have reported to be wanting to be
involved in the decision making about their health care (Reeve et al., 2018). According to
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physicians, patient’s unwillingness to stop the medication or patient resistance is one of the main
factors that prevents deprescribing (Reeve, 2018). Patient engagement is essential for the safe and
effective use of medications. Patient perspectives on the medications and the willingness to
discontinue a medication is notably absent in the nationally representative data (Reeve et al.,
2018). It has been suggested that if some classes of medications are stopped in older adults, it
would not worsen the clinical outcomes and can help improve the fall risks, behavior and cognition
of the patient (Iyer et al., 2008). The patient centered approach to deprescribing can improve the
medication adherence among the patients and can further help increase the patient satisfaction
regarding the treatment. Hence, the goal of our study was to explore the attitudes of older adults
with osteoporosis towards deprescribing. Additionally, we sought to identify the socio-behavioral
factors predicting willingness towards deprescribing among older adults with osteoporosis.

LITERATURE REVIEW
Osteoporosis-related fractures are a worldwide public health concern. The risk factors for
osteoporotic fractures include age, gender, race, geographical region, diet, lifestyle, hormonal
status, bone density, bone quality, body mass index and medical comorbidities (Dontas &
Yiannakopoulos, 2007). The lifetime risk of any osteoporotic fracture at the age of 50 years and
above has been estimated to be 40% in women and 13% in men in USA (Johnell & Kanis,2005).
The major rationale for initiating an anti-resorptive treatment among the patients with osteoporosis
is that the risk of further fractures is 2-4 times, and the mortality is 2-3 times greater for someone
with fragility fracture as for other people of the same age (Eisman, 2019). The prevalence and risk
of osteoporosis increases as a person ages but differs by gender, race, and ethnicity of the person
(Looker et al., 2012).
5

Polypharmacy and Osteoporosis Polypharmacy and consumption of potentially
inappropriate medications (PIMs) are associated with increased risk of ADRs, geriatric syndromes,
hospitalizations, morbidity, mortality, and the associated financial costs which can worsen the
health outcome of the patient. (Reeve et al., 2015). There are many risk factors for polypharmacy
such as demographics, health status of the patient and the access to the health care services (Hajjar
et al., 2007). A clinical trial of polypharmacy reduction in older adults showed that over half of
the medications can be discontinued and only 2% of medicines had to be restarted because of the
recurrence of the original health condition (Gnjidic, 2012). The problems of polypharmacy are
prevalent among older adults and there is a risk of potential interactions of osteoporosis
medications like oral and parenteral bisphosphonates, raloxifene, strontium ranelate, teriparatide,
denosumab drugs with other medications a person might be on. It can be inferred that several
drugs may have the negative effect on the bone metabolism of a person and these drugs can lead
to increased fracture risk and risk of falls (Gosch et al., 2012).
Inappropriate prescribing (IP) along with polypharmacy is prevalent among older adults.
IP refers to mis-prescribing, overprescribing or under prescribing of the medications in context of
the patient’s co-morbidities, medication regime, functional and cognitive status of a person along
with the treatment goals and life expectancy (Lavan, et al., 2017). There are approximately 2060% of elderly patients consuming at least one potentially inappropriate medication (PIM) (Reeve
et al., 2013). The risk factors of inappropriate medications include older age, polypharmacy and
multiple attending physicians and pharmacists (Spinewine et al., 2007). The consumption of PIMs
can result in adverse outcomes in patients such as adverse drug reactions, increased
hospitalizations, and mortality (Dedhiya et al., 2010; Chrischilles et al., 2009). Frail patients
especially may have limited life expectancy. The medication review of these patients should
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primarily focus on the deprescribing of medications and symptom management rather than
aggressive preventative strategies (Lavan et al., 2017).
Deprescribing and patient-centered care. Deprescribing in layman terms, is the process
of stopping or tapering of medications which further would improve the patient outcomes and
would help optimize the current therapy a patient might be on (Qi, K et al., 2015). Reeve et.al.
(2013), attempted to define the term “deprescription” by conducting a review. The definition
proposed by Reeve and colleagues is – “Deprescribing is the process of withdrawal of an
inappropriate medication, supervised by a health care professional with the goal of managing
polypharmacy and improving outcomes” (Reeve et al., 2015). Evidence from studies suggests that
deprescribing is associated with improvements in quality of life and survival of the older patients
(Qi, K et al., 2015). It may lead to increased patient adherence to the medication as it provides an
option to individualize the medication dosage and further helps improve patient-professional
relationship (Woodward, 2003; Le Couteur, 2011). Schuling, et al. (2012) suggested that although
general practitioners are in favor of a patient-centered approach, they still do not inquire into the
patient’s preferences or discuss the treatment goals of the patients.
Deprescribing is a relatively new term, which shifts attention to a sometimes-overlooked
step in the medication review of stopping medications to improve health outcomes and decrease
the risk of polypharmacy (Frank & Weir, 2014). A patient-centered deprescribing process may
also help to reduce the financial cost of the patient (Reeve, et al., 2014). In order to improve the
overall experience of the patient, it is essential to understand the patient’s views and preferences
about the pharmacotherapy, their willingness to have the medications deprescribed and ultimately
take into consideration their views to achieve a patient centered care (Reeve, et al., 2014). Reeve
and colleagues published a systematic review based on 21 studies and reported that the patients
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who believed that the medication was no longer appropriate, tend to lead to the cessation of the
medication (Reeve et al., 2013). For a treatment plan to be successful, it is necessary to consider
patient’s perspective on what aspects of treatment are important to him. Studies so far have not
considered the potential important drivers of patient preferences such as medication effectiveness,
side effects, costs, medication convenience, ease of use etc. which might further drive their views
on deprescribing. Although, catalyst to deprescribing among the older adults should be ‘frailty’,
the principles and practice of deprescribing applies to all older adults and can help preventing
frailty (Rockwood, et al., 1999).
Various qualitative studies done among older adults have identified factors which might
influence the patient’s willingness to have a medication withdrawn. Safran et. al., (2005) found
that the reason Medicare beneficiaries were non-adherent to the medications was because the
medications were making them feel worse, or the patient believed that the medication was not
helping them. Additionally, 15% of the Medicare beneficiaries reported that they did not believe
they needed the medication, or they were already taking too many medications (Safran, D.G., et
al., 2005). Mazor, et al. (2010) found that older women’s views regarding perceived need,
effectiveness, and safety about the prescription drugs for treating osteoporosis were the drivers of
the use of prescription osteoporosis medication (Mazor, K.M., et al., 2010). The WHO Guide to
Good Prescribing encourages that patients and their family members should be partners in the
prescribing process and should be at the center of the deprescribing process so as to customize the
treatment according to the patient and improve health outcomes. (Reeve et al., 2016).
Patient’s willingness towards deprescribing In 2013, to determine people’s attitudes and
beliefs towards the withdrawal of the medication and understand the patient’s perspective towards
deprescribing, Reeve and colleagues developed the Patients’ Attitudes Towards Deprescribing
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(PATD) questionnaire (Reeve et al., 2013). The PATD questionnaire explores the views and
beliefs of the patients regarding the cessation of the medications. The PATD questionnaire consists
of questions related to deprescribing such as ‘, ‘If my doctor said it was possible I would be willing
to stop one or more of my regular medications’, and ‘I believe that I have a good understanding of
my medications’ (Reeve et al., 2015). One of the limitations of PATD is that there is no scoring
system, it is completely exploratory, and does not capture all the potential barriers and enablers of
deprescribing. Secondly, there is no version for family members and caregivers who are involved
in the healthcare decisions for the older adults. Keeping these limitations in mind, a revised version
of PATD questionnaire (rPATD) was developed by Reeve et al., (2016). The rationale behind
rPATD was to quantitively capture beliefs and attitudes of patients towards deprescribing with
separate versions for older adults and caregivers.
The rPATD questionnaire contains four factors which are- patient’s belief in
appropriateness of medication withdrawal; perceived burden of their medications; concerns about
stopping the medication and level of involvement in decision making towards the medication
management. The appropriateness factor includes patient’s belief in need and effectiveness of
medication. The burden factor includes inconvenience that might be caused to the patient such as
cost, stress etc. The involvement factor represents the perceived involvement and self-reported
knowledge of the patients about their medications. Additionally, two global questions are included
which are ‘If my/their doctor said it was possible, I would be willing to stop one or more of my/my
care recipient’s regular medicines’ and ‘Overall, I am satisfied with my/my care recipient’s current
medicines’ (Reeve et al., 2016).
Health Belief Model To learn how the individuals, make decisions about their health and
what determines their health behavior, in the early 1950’s Health Belief Model was developed.
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The model was developed by Rosenstock, Hochbaum, and others, from their vantage point at the
U.S. Public Health Service (Glanz et al., 2008). The Health Belief Model (HBM) contains various
concepts that help predict why an individual will take action to prevent, screen or control illness
conditions (Glanz et al., 2008). The Health Belief Model is one of the most widely applied theories
of the health behavior (Jones et al., 2015). The Health Belief Model (HBM) consists of six
constructs which help to predict the human behavior. The six constructs are: risk susceptibility,
risk severity, benefits to action, barriers to action, self- efficacy, and the cues to action (Strecher
& Rosenstock,1997). According to the Health Belief Model, an individual will act towards a
behavior only if: 1) they regard themselves being susceptible to that disease/condition 2) if the
individual believes that the condition would result in potentially severe consequences 3) if he/she
believes that a particular action which is available to them would help them reduce the
susceptibility or severity or even lead to any other positive outcomes 4) and if the individual
perceives few negative attributes related to the health action such as cost, time etc. The selfefficacy construct is the belief of an individual that he/she can successfully engage and complete
the behavior of one’s interest despite the barriers which might come along the way (Champion &
Skinner, 2008). The HBM model also suggests that there are some factors in an individual’s
environment which further impacts the final action one takes. These factors are termed as ‘cues
to action’ and can be internal or external (Jones, 2015).
The components of the HBM are depicted in Figure 1. The arrows in the figure indicate
the relationships between the constructs of the model. Modifying factors consists of demographic
variables such as age, race, gender, and region of the census of SP. Health beliefs includes the
major constructs of HBM: susceptibility, severity, benefits, barriers, and self-efficacy. Modifying
factors and the cues to action affect the mentioned individual health beliefs. The combination of
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these beliefs further leads to a behavior. The perceived susceptibility and severity can be combined
to identify the perceived threat. The relationship among the constructs of the HBM is not welldefined. Hence, because of this ambiguity in the relationships of the constructs there are variations
in the HBM applications. Patients make decisions to take the medication based on their individual
perceived risk in relation to the perceived benefit of the activity in which they are engaging.
Perceived risk in the medication behavior would be the patient’s perception of medication
attributes of the osteoporosis medications like cost, convenience, efficacy, and side effects (Weiss,
et al., 2006).

Modifying Factors

DEMOGRAPHICS

Individual Beliefs

Action

Perceived Susceptibility

AGE
RACE
GENDER

Perceived Barriers
Self - efficacy

Willingness
towards
deprescription

REGION

Perceived Benefits
Perceived Severity
Cues to Action

Fig 1: Health Belief Model Components and Linkages.

Osteoporosis and Health Belief Model There have been a few studies done in
osteoporosis which have utilized the Health Belief Model. The Unson study found that if a person
11

perceives himself/herself susceptible to the illness, evaluates that the outcomes of the illness can
be serious, and thinks that the benefit of the treatment will outweigh the cost, then the likelihood
of the person’s adherence to the treatment will increase. It further emphasizes the need of the
shared decision making which should be centered around the patient’s perception of severity,
susceptibility, benefits, side effects and affordability of the treatment options (Unson, et al., 2003).
Yood et al. (2008) suggested that the treatment initiation is said to be affected by the
patient’s beliefs about the disease severity, medication effectiveness, safety, and the side effects
of the treatment. These findings were consistent with the Health Belief Model. They concluded
that the patients who initiated the therapy were more likely to believe in the effectiveness of the
osteoporosis treatment. They were more prone to agree to the statements like “taking osteoporosis
medication is good for me” and less likely to agree with “medications often cause more problems
than they solve” or “I worry about the side effects of taking osteoporosis medication”. (Yood,
2008). Additionally, The PREFER- International study’s results demonstrate that the patients were
most adherent to the health recommendation if they were motivated about their health. Hiligsmann
and colleagues also showed that osteoporosis patients have preferences for medication attributes
and are willing to trade between these attributes when making a treatment choice for themselves.
Patients prefer higher efficacy of the medication, lower cost and less frequent dosing regimens
while taking a treatment. (Hiligsmann et al., 2014).

RESEARCH OBJECTIVES
1. To describe willingness toward deprescribing among older adults with osteoporosis
2. To identify the socio-behavioral factors predicting willingness toward deprescribing
among older adults with osteoporosis
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METHODOLOGY

Study design This study was a retrospective cross-sectional, observational study using the
National Health & Aging Trends Study data from Round 6 (2015).
Data Source The National Health and Aging Trends Study (NHATS) is a nationally
representative dataset that gathers information on Medicare beneficiaries aged 65 years and older
living in United States. NHATS oversamples non-Hispanic Blacks and individuals above 90 years
to investigate trends in late-life functioning (Kasper et al., 2017). NHATS began gathering the
information from 2011 onwards with data collection involving annual, in-person interviews with
detailed information on the disabilities due to age and its consequences on the Medicare
beneficiaries (Kasper, 2014). The data collection occurs annually and involves in-person
interviews with the participants referred to as sample person (SP) or proxy (if the sample patient
is not able to respond) and contains information such as demographics, physical and cognitive
capacity, living social and technological environment, the economic status of the participant, end
of life care quality, health characteristics (Reeve et.al,2018). The NHATS public use data contains
the weighted analysis of Medicare beneficiaries aged 65 and older living in the contiguous United
States since September 30, 2010. The weighted response rate in 2015 (Round 6) was 88.5%
(sampling weights take into account the survey nonresponse and differential probabilities of
selection) (Kasper et.al., 2017). Sampling weights and stratification units are provided to account
for the NHATS complex sampling design and to help generalize results to the broader population
of older adults in the US. The NHATS files can be linked to one another using the unique variable,
“SPID” (Sample Person ID). There are data collection instrument booklets present for all the 9
rounds administered by NHATS from the year 2010 to 2018. The data collection instrument has
various sections of the topics and modules administered in each round such as Housing type (HT)
13

module, Health conditions module (HC) module etc. (NHATS Data Collection Procedures: Round
6, 2016). NHATS also focuses on physical function using standardized assessments rather than
self-reported data alone with trained staff assessing the cognitive and physical functioning inperson in participants’ homes. Details about the physical activity assessment is available in the
performance activity booklet of NHATS (Kasper et al., 2012).
Timeline The National Health & Aging Survey data from 2015 (Round 6) was used in this
study. The study was restricted to this year of data because the Medication Attitudes Module,
which contains key question essential to this study, was administered only in Round 6 of the
NHATS. The NHATS public use data as mentioned previously, uses the weighted analysis of the
Medicare beneficiaries living in United States since September 30, 2010. The original cohort has
been interviewed annually since then. The replenishment of the sample took place in Round 5 to
restore the sample to original sizes by age and race groups. The eligible participants added in the
sample replenishment were the Medicare beneficiaries who were of age 65 years and older as of
September 30, 2014. Participants added in the sample replenishment are referred to as “new
sample” and the participants from the original 2011 cohort are referred to as the “continuing
sample”.
Inclusion/Exclusion Criteria In order to be eligible for the study, the participants must
have/had reported being diagnosed with osteoporosis in Round 6 or earlier. The key construct
evaluated in this study, willingness toward deprescribing, is assessed as part of the Medication
Attitudes Module, which is only administered to a random one third of the NHATS respondents.
Therefore, patients diagnosed with osteoporosis who were not administered the Medication
Attitude module were excluded from the study. Because the objective of our study was to study
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the patient’s (Sample person) attitude towards deprescribing, data collected from proxy
respondents were also excluded.
Operationalization
Dependent Variable
Willingness Towards Deprescribing
The operationalization of the dependent variable in this study relied on the NHATS
Medication Attitudes module, which was administered to the one-third of the respondents
(unweighted, n = 2,124 out of 7,099) in Round 6 (Kasper, Judith D., et al., 2017). The Medication
Attitudes module contains 10 questions which are derived from the Patients’ Attitudes Towards
Deprescribing (PATD) questionnaire and revised PATD (rPATD) questionnaire (older adults’
version) (Reeve et al., 2018). These questionnaires were designed to assess the individuals’
attitudes, beliefs, experiences with respect to their medications and the potential withdrawal of 1
or more of their medications. The construct validity, face validity, criterion validity, content
validity, and the internal validity as well as the test- retest reliability of these questionnaires have
been established in a population of Australian older adults with multiple chronic conditions and
multiple medications (Reeve et.al., 2015).
The questions in the Medication Attitude module are from the 4 domains of the rPATD
and PATD questionnaires namely, burden, appropriateness, concerns about stopping medications
and involvement in the decision making (Table 2). The module has questions like “If my doctor
said it was possible, I would be willing to stop one or more of my regular medicines”; “I have a
good understanding of the reasons I am taking each of my medications”; “I would like to reduce
the number of medications I am taking”; “I get stressed whenever changes are made to my
medications” (Reeve et. al., 2016). Eight statements out of ten asked in the module have response
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categories of “strongly agree,” “agree,” “disagree,” and “strongly disagree.” The two last final
questions in the module are derived from the PATD. These questions are: About how many
different regular medicines do you take?” and “What is the maximum number of pills that you
would be comfortable taking daily?” The later question is administered with a series of 6
photographs of an increasing number of pills as response options for the participant to choose
from. (Reeve et.al, 2018).
We utilized one question from the module for our analysis as we believed this question
covered the area of wanting to reduce medications, which is an important criterion to evaluate the
willingness toward deprescribing. “Wanting to reduce” was estimated from the response to the
question: “You would like to reduce the number of medicines you are taking”. Respondents who
selected ‘agree’ or ‘strongly agree’ to this question were classified as being receptive toward
potential deprescribing and vice-versa.
Independent Variables
The independent socio-behavioral factors included as predictors of willingness toward
deprescribing in this study were chosen from the available constructs in NHATS using the HBM
as a theoretical framework. The independent variables measured in this study included
demographic variables, variables assessing Perceived susceptibility, Perceived barriers, Selfefficacy, Cues to action and Perceived severity (Table 1).
Demographics
The demographic variables included in this study were age, sex, race and region. Age was
divided into three categories: 65-74, 75-84, >= 85. Male and female gender were used to represent
the sex of the participant. The race of the participant was identified as White Non-Hispanics, Black
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Non-Hispanics, and others. Lastly, the region of the Sample Person’s (SP) residence at the Census
Division level was divided into Northeast region, Midwest region, South region, and West region.
Perceived Susceptibility
Medication burden Respondent’s medication burden was assessed using the question
administered as part of the Medication Attitudes Module. The SP was asked “About how many
different regular medicines do you take?”. The SP was given the following options to choose from:
1-2; 3-5; 6-10; 11-15; 16-20; more than 20/refused/ don’t know.
Overall health condition This variable was measured by the response to the question:
“Would you say that in general your health is excellent, very good, good, fair, or poor?”.
Number of comorbid conditions This variable represented the other comorbid disease a
sample patient had other than osteoporosis. The available options for the respondent to choose
from were heart attack or myocardial infraction; any heart disease like angina and CHF;
hypertension; arthritis; diabetes; lung disease; stroke; dementia; cancer.
Self-efficacy
Use of technology for health purposes This variable was measured by the response to the
question: “In the last year, have you gone on the Internet or online to a. contact any of your medical
providers? b. handle Medicare or other health insurance matters? c. got information about your
health conditions?”. If the SP answered Yes to at least one of the three questions, the SP was
considered utilizing technology for health purposes.
Ability to perform tasks This variable was measured by the response to the question: “For
these last few statements, please tell me if you agree a lot, a little, or not at all. (a). Other people
determine most of what I can and cannot do. (b). When I really want to do something, I usually
find a way to do it. (c). I have an easy time adjusting to change”. To analyze this variable, we
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reverse coded the responses to the first question (a), and then summed up the responses to all the
three questions. Lastly, we categorized the SP’s to have a lower self-efficacy if the sum of all the
three questions was less than/equal to 5 and higher self-efficacy if the sum was greater than/equal
to 6 (Vicki Simpson and Dongjuan Xu, 2020).
Perceived Barriers
Assistance with doctor This variable was measured by the response to the question:
“During those visits in the last year, did the person from the place where you live ever [c] remind
you about things you wanted to ask or tell the doctor? [d] ask or tell the doctor things for you? [e]
help understand what the doctor was saying?”. The response options were yes; no/refused/don’t
know. We determined if the respondent answered “yes” to any of the above question and if they
did, it implied that they needed assistance with the doctor.
Insurance Plans Using six variables in the Insurance Plan instrument booklet, we
identified the patient’s insurance coverage. Patient’s insurance plan was classified as being
covered if the SP selected one the given options provided to them - Medicare Part D, employer
sponsored coverage, Medicaid, or Tricare.
Perceived Severity
Fall risk As osteoporosis progresses, the risk of falls in these patients increases gradually.
Estimating patients for risk of falls is an essential component of osteoporosis management and
prevention of falls (Berk et al., 2019). Estimating the risk of falls also provides an estimate of the
potential health risks of the patient. We calculated the fall risk of the participant using the
Performance activity booklet in the NHATS. Fall risk was calculated as per Crow and colleagues
(2018) using the adapted version of the STEADI (Stopping Elderly Accidents, Deaths, and
Injuries) algorithm, originally developed by Stevens and Phelan (2013). STEADI is a fall
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prevention toolkit for the health care providers for fall risk assessment and management. (Crow
et.al., 2018). NHATS uses the adapted STEADI measure, which is specific to fall risk, as it predicts
fall occurrence independent of general physical health and risk of mortality (Figure 2). According
to the STEADI algorithm, if the participant has answered the questions-“Have you fallen in the
last year?”, “Are you worried about falling down?”, and “Do you have problems with balance and
coordination?” with a “no”, they will be labeled as being at low risk of falls. On contrary, if they
answered “yes” to at least one of the above questions, then they will be further stratified using the
physical functioning test score. To estimate the physical functioning test score, NHATS
administers the Four-Stage Balance Test and Five-Time Sit to Stand (FTSTS) Test. These tests
evaluate the lower extremity strength of the participants, which is associated with the dysfunction
in balance and mobility (Whitney et.al., 2015). According to CDC, an older adult taking the test,
who is unable to hold a tandem stance for at least 10 seconds is at a greater risk of falling (Stevens
& Phelan, 2013). Participants are also at a greater risk of falling if they complete less than 5
repetitions of FTSTS test in 15 seconds (Buatois et.al.,2008). If both the Four stage balance and
the FTSTS tests were completed by the participant, they were classified as being at lower risk of
falls. If the participant was unable to complete either of these tests, they were stratified according
to their response to the questions: “Have you have multiple falls in the last year?” and “Have you
broken a hip since age 50?”. If they answered “yes” to either question they were categorized as
being at higher risk of falls. A “no” to both questions led them to be classified as having an
intermediate risk of falls. Participants who were deemed ineligible for physical assessments
because of pain, recent surgery, or lack of facilities were considered missing on the respective
physical measures.
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Frailty Frailty can be defined as “a biologic syndrome of decreased reserve and resistance
to stressors, resulting from cumulative declines across multiple physiologic systems, and causing
vulnerability to adverse outcomes” (Fried et al., 2001). Frailty of an individual was operationalized
based on criteria used by Crow et. al. (2018), using 5 phenotypic criteria, originally developed as
per the cardiovascular health study (Fried et.al., 2001). These phenotypic criteria were
unintentional weight loss (10 lbs. in past year), self-reported exhaustion, weakness (grip strength),
slow walking speed, and low physical activity (Fried et.al., 2001). We assessed each of these 5
phenotypic criteria using self- reported responses to the NHATS survey. Unintentional weight loss
was measured as weight loss of 10 pounds in the last year without trying. Self-reported exhaustion
was identified if the patient agreed with at least one of the following two questions- “In the last
month, did SP have low energy or was easily tired?” (easily exhausted); “In the last month, did
low energy or exhaustion ever limit SP’s activities?” (limiting activities). Weakness was
operationalized as individuals in the bottom 20 th percentile of grip strength (measured using
maximum dominant hand grip strength over 2 trials) in 8 sex-by–body mass index (BMI)
categories. The BMI categories used for the estimation of the percentiles were: Underweight: BMI
<18.5; Normal: BMI 18.5-<25; Overweight: BMI 25-<30 and Obese: BMI >= 30, each for males
and females. Slow walking speed was defined as being in the bottom 20th percentile of gait speed
(estimated as the first of 2 usual-pace walking trials) within 4 sex-by-height categories. These
categories were Female, <=159 cm; Female, >159 cm; Male, <=173 cm; and Male, >173 cm
(Bandeen-Roche, et al., 2015). Participants met the criteria for low physical activity, if recently,
they never exercised or engaged in vigorous activities based on the question “In the last month,
did SP ever go walking or exercise?”. For each participant not tested because of the safety
concerns, being ineligible due to recent surgery or pain, or who attempted but were unable to
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complete the test, they were assigned “0” for that particular practice. Participants who met 0 of
the five phenotypic criteria were classified as robust, those who met 1 or 2 were classified as
prefrail, and those who met 3 or more were classified as frail. (Bandeen-Roche, et al., 2015).
Cues to Action
Difficulty swallowing This variable was measured by the response to the question: “In the
last month, did you have problems with chewing or swallowing that caused difficulty when you
ate?” The response was recorded in a Yes/No format.
Regular visits to doctor This variable was measured by the response to the question:
“Have you seen your regular doctor/ a doctor within the last year?.” The respondents had a choice
to select yes/no, refused, don’t know.
Statistical Analysis All the analysis and data management were performed using SAS
version 9.4 (Cary, NC). Descriptive statistics were generated for all individual characteristics of
the eligible population in this study, including willingness toward deprescribing, using frequencies
and percentages. We performed binary logistic regression with a scale statement from the
Medication Attitude module as the main study outcome, as previously described. Patient responses
to the ‘wanting to reduce’ question was converted to a binary outcome of agree (strongly agree or
agree) and disagree (disagree or strongly disagree), in order to conduct a binary logistic regression.
Multivariable logistic regression model included key predictor variables as described above
including patient demographics and other clinical characteristics. All the tests were conducted with
an apriori alpha level at 0.05. All analyses were conducted using PROC SURVEYFREQ, PROC
SURVEYLOGISTIC, PROC SURVEYMEANS, and other survey procedures utilizing the
analytical weights of the NHATS in order to obtain weighted national estimates.
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RESULTS
Older Adults’ Characteristics
A total of 555 unique individuals accounting for a weighted sample of 3,127,772
individuals were found to be eligible for the study. Of the eligible older adults, 41.66 %
(unweighted n=149) were 65 to 74 years old, 38.63 % (unweighted n=238) were 75 to 84 years
old, and 19.71 % (unweighted n=168) were 85 years and older. Women made up 88.18%
(unweighted n=483) of the respondents, and 81.20% (unweighted n=405) were White NonHispanics, 36.84% (unweighted n = 218) belonged to the South region, and 56.49% (unweighted
n=272) reported having least 2 chronic medical conditions (Table 3).
Older Adults’ Willingness Toward Deprescribing
Of the total cohort of 555 respondents, a majority i.e., 62.86% (unweighted n=336) were
willing to reduce the number of medications they take. In bivariate relationships, a significant
association was found between respondents’ perception of their health and their willingness
towards deprescribing (Excellent/Very good vs Good vs Fair/Poor: 50.57% vs 70.81% vs 67.57%;
p = 0.001). A similar association was observed with the medication burden of the respondent as
well (0-2 vs 3-10 vs >10 medications: 41.29% vs 63.60% vs 88.65%; p <0.0001). Lastly, fall risk
was also associated with willingness to deprescribe (high vs moderate vs low: 69.00% vs 73.39%
vs 58.88%; p = 0.04).
When asked if the respondents would like to reduce the number of medications they
consume, respondents who visited the doctor regularly (63.23% vs 55.95%; p = 0.56), had high
ability to perform the daily tasks (72.23% vs 64.19%; p = 0.32) and who did not have health
insurance coverage (66.52% vs 62.59%; p = 0.68) were seen as being more receptive towards
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deprescribing compared to their counterparts who did not meet these criteria, even though these
differences were not statistically significant. Furthermore, respondents who did not use technology
for health purposes (63.07% vs 62.34%; p = 0.91), had difficulty in swallowing (70.35% vs
62.00%; p = 0.24), were diagnosed with 5-8 chronic conditions (5-8 vs 3-4 vs 0-2 conditions:
76.27% vs 66.42% vs 59.10%; p = 0.13), and those who were classified as frail (frail vs pre-frail
vs robust: 67.72% vs 62.57% vs 61.74%; p = 0.83) were also seen to be more inclined toward
wanting to reduce the number of medicines. These differences were also not statistically significant
(Table 3).
This study used the Health Belief Model to identify predictors of willingness to deprescribe
medications among older adults with osteoporosis. Results from the multivariable logistic
regression model depicting adjusted odds ratios are presented in Table 4. However, among
variables identified by this theoretical framework, we found that only two predictors were
significantly able to predict the willingness towards deprescribing. First, we found that odds of
wanting to reduce the number of medications for those taking 3-10 medications relative to those
taking at least 2 medications were significantly more (OR 2.42; 95% CI,1.20-4.86). Similarly, the
odds of wanting to reduce the number of medications for those taking more than 10 medications
relative to those taking at least 2 medications were also significantly higher (OR 14.66; 95% CI,
5.36-40.11). Additionally, respondents who were 85 years and older had significantly lower odds
of wanting to reduce the number of medications relative to respondents aged between 65 to 75
years (OR 0.45; 95% CI, 0.23-0.89).

24

DISCUSSION
Existing evidence from peer-reviewed literature supports the benefits and safety associated
with deprescribing, including improvements to health and quality of life of the patients, as well as
the cost benefits to healthcare expenses (Reeve et al., 2014; Reeve et al., 2013). Previous studies
show that patient’s perspectives and beliefs constitute important factors for successful medication
discontinuation (Linsky et al.,2015). However, the factors associated with the patient preferences,
specifically within certain disease states associated with high prescription burden – such as
osteoporosis – have been unclear. For example, previously conducted qualitative studies showed
inconsistent results regarding the association between polypharmacy and patients’ willingness to
deprescribe. Sirois and colleagues (2017) observed an association between number of medications
the patient is consuming and their willingness to deprescribe. On the other hand, Qi and colleagues
(2015) did not find a similar association. Nevertheless, successful medication discontinuation or
deprescribing can help reduce pharmacy costs, decrease adverse drug events, use of healthcare
resources, and ultimately help improve the patient’s adherence to their medication regimen (Reeve
et al., 2014).
To our knowledge, this is the first nationally representative study capturing willingness
towards deprescribing among older beneficiaries diagnosed with osteoporosis. Respondent’s
willingness to deprescribe was assessed utilizing a question from the patients’ attitudes towards
deprescribing (PATD & rPATD) questionnaire. These questionnaires were developed by Reeve
and colleagues. This tool has also been tested for its validity and reliability (Reeve et al., 2016).
Our patient population consisted of older adults who were 65 years or older and were diagnosed
with osteoporosis. Most of our cohort comprised of female respondents (87.03%). Additionally,
most respondents were consuming 3-10 medications regularly (68.12%) and our cohort comprised
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of a majority of White Non-Hispanics (72.97%). Our study used the data from a nationally
representative NHATS cohort and found that most of the eligible population were receptive
towards deprescribing, which is consistent with findings from other studies using the rPATD
questionnaire internationally (Reeve et al., 2018; Linsky et al., 2015). In our study, 62.86% of
respondents reported that they would like to reduce the number of medications they are taking
regularly. This finding was similar to the qualitative study conducted by Linsky et al. (2015) where
they identified the patient perspectives on the intentional medication discontinuation and found
most of the participants wanted to reduce their number of medications as well. Additionally, Reeve
et al. (2018) in their study to explore attitudes of older adults towards deprescribing, also found
that approximately 70% of their cohort wanted to reduce the number of medications.
We included all the predictors selected by us in the multivariate model on the basis on
health belief model. To our surprise, only two of the variables showed significant results in the
binary logistic regression. In our model, we found that age was significantly associated with
patient’s willingness to deprescribe (OR 0.45; 95% CI 0.23-0.89). This finding was somewhat
different from the findings of Takuya et al. (2018), where they investigated the factors associated
with patient preferences towards deprescribing. They found that the association of age and the
willingness to deprescribe had an odds ratio of 1.12 (95% CI 1.04-1.20). The second factor that
showed a significant relationship with patients’ willingness to deprescribe medications, was the
medication burden of the respondent. We defined the medication burden of the respondent as the
number of medications they were taking regularly. Previous studies in this area have reported
mixed results for the association between the number of medications consumed and patients’
willingness to deprescribe. Some studies found that willingness to deprescribe increases with
number of medications, (Sirois et al., 2017) but some studies did not find a similar relationship
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(Reeve et al., 2013; Qi et al., 2015). Individuals’ willingness to deprescribe may also be influenced
by their perception of the number of medicines they consume.
No significant association was found between the demographic variables such as sex,
region, and race to the willingness to deprescribe the medication, which is similar to the studies
conducted in Japan, Australia and USA. Study conducted in Japan by Takuya and colleagues
(2018) found no association of the demographic factors except age to the patients’ willingness to
deprescribe. Reeve and colleagues (2018) conducted a similar study in Australia and found the
same results. In United States, Komagamine and colleagues (2018) decided to investigate the
factors associated with the deprescribing refusal among elderly patients and found no association
with the demographic factors. Our study results did not find adequate evidence to conclude that
there is an association of the other predictors which we included in our model and willingness to
deprescribe.
In our bivariate tests of association, we found a U-shaped relationship between
respondent’s health perception and their receptiveness towards deprescribing. We observed that
respondents who considered themselves as being in good health were more willing to reduce the
number of medications (70.81%). We believe that the respondents who considered themselves to
be in an excellent/very good conditions were less receptive towards deprescribing (50.57%)
because they probably were satisfied with their current treatment and did not think that reducing
the medications would help improve their health any further. On the other hand, respondents who
considered their health as fair/poor (67.57%) were receptive probably due to concerns regarding
the adverse effects of polypharmacy or because of beliefs that reducing the number of medications
would improve their health. However, this relationship between respondent’s health perception
and their receptiveness towards deprescribing becomes non-significant in our multivariable model.
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This aligns with what Takuya and colleagues mention in their paper regarding the associations of
possible clinical factors including the presence of multiple chronic health conditions, and health
status with willingness to deprescribe being unclear in the past (Aoki et al., 2018). Additionally, a
significant relationship was observed between the fall risk of the respondent and their
receptiveness towards deprescribing. We believe that this might be because respondents might
think that taking a greater number of medications puts them at a higher risk of falls. This fact has
been pointed out by Hartikainen and colleagues that the risk of falls is associated with
polypharmacy (Hartikainen et al., 2007).
There can be various reasons associated with why the respondents in our cohort indicate
willingness to deprescribe medication. The first reason might be that the medications are making
the respondents feel worse, or they do not believe that the medication is helping them improve
their medical condition (Safran, D.G., et al., 2005). Currently, there is not much guidance available
for providers to effectively communicate to patients about medication discontinuation despite
many patients’ wanting to stop the medications they are taking (Linksy et al., 2015). Patient
centered approach to treatment plays an essential role for the patients’ medication adherence as
well. Discontinuation of medications, if done prior to side effects, can also lead to improved health
outcomes (Iyer et al., 2008).
Incorporating deprescribing process can not only help patients improve their quality of life
and health outcomes, but it can also help improve the patient-professional relationship and increase
patient satisfaction with the treatment (Reeve et al.,2013). Reeve and colleagues in their review
on patient reported considerations in the decision to stop medications enlisted many barriers that
contribute to not initiating the deprescribing process. These patient-reported barriers include lack
of support by their providers, fear of negative consequences related to deprescribing, the
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complicated process, and poor past experiences with ceasing medications (Reeve et al.,2013). That
said, it is essential for the healthcare professionals to have a good knowledge of the patient reported
barriers and enablers to deprescribing. Understanding patients’ perspectives regarding treatment
can further help develop the guidelines, deprescribing interventions, and education material for
patients and clinicians (Rozsnyai et al., 2020). Fried and colleagues in their study reported that the
healthcare decision making is very disease focused, which results in ignorance of serious adverse
outcomes it can cause in older adults who are exposed to polypharmacy and already have other
comorbid conditions (Fried et al., 2008). To implement deprescribing, it is essential to find out the
patient’s perceived burden, so that discussion about deprescribing can be targeted accordingly by
the physician and can further result in a better health outcome for the patient. (Herzig et al., 2019).
We believed that the Health Belief Model can help predict the factors that influence the
patient’s willingness towards deprescribing. We expected to find significant associations of other
predictors in our model from the different constructs of HBM and their willingness towards
deprescribing. We believe that the future studies can utilize other theoretical models to understand
this topic better. The key advantage of our study was its use of data from a nationwide
representative sample of NHATS, which allows for generalization of its results to the wider
population. Our study has several limitations. One of the limitations in our study is the small,
unweighted sample size. While we do not believe this affects the generalizability of our findings,
our logistic regression model was underpowered as a result. Second, several variables that are
traditionally included in applications of HBM could not incorporated in this study because of their
lack of availability in the NHATS dataset. We could also not evaluate appropriateness of the
medications, which can help us assess need for deprescribing. Future studies should explore these
results using a survey of older adults with osteoporosis in order to extend our findings. Finally, the
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MA module is validated in Australia and not formally validated in the United States. While we do
not believe that this affects the validity of our findings, future research should focus on validating
the PATD in scale in the United States.

CONCLUSION
This study found that 62.86% of the respondents diagnosed with osteoporosis who were
administered the Medication Attitude module were willing to deprescribe their medication. In
addition, perceived health, fall risks, and medication burden were associated with the respondent’s
willingness towards deprescribing. The study also suggests that the odds of respondents wanting
to reduce the number of medications for those taking 3-10 medications and more than 10
medications relative to those taking at least 2 medications are significantly higher. Lastly,
respondents who were 85 years and older had fewer odds of wanting to reduce the number of
medications relative to respondents aged between 65 to 75 years.
The management of treatment among older adults is challenging, mainly because the
problem of polypharmacy is common among them. Healthcare providers also need to take into
consideration the patient’s views regarding their treatment regimen. This study has filled an
important gap in the field of deprescribing by identifying the potential factors that may guide
willingness of patients diagnosed with osteoporosis towards deprescribing.
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Table 1: Variables used to predict willingness to deprescribe
Independent
variable
category

Demographics

Variable name

NHATS variable
name

Question asked in NHATS

Age

FQ24

What is your date of birth?

Gender

FQ22

THE SP IS LISTED AS A
{MALE/FEMALE}

Race

rl5dracehisp

Region

re6dcensdiv

Census division the respondent belonged
to

Overall health
condition

hc6health

Would you say that in general your
health is excellent, very good, good, fair,
or poor?

Number of
comorbid
conditions

hc6disescn1
hc6disescn2
hc6disescn3
hc6disescn4

We are interested in new health
conditions that you have learned about
this year. Since the time of the last
interview in {LAST INT MONTH AND
YEAR}, has a doctor told you that you
had

Perceived
Susceptibility

hc6disescn6
hc6disescn7
hc6disescn8
hc6disescn9
hc6disescn10
Medication
Burden

ma6medsnum

About how many different regular
medicines do you take?

hc6worryfall

In the last month, did you worry about
falling down?

hc6faleninyr

Since {LAST INT MONTH AND
YEAR} have you fallen down?

ss6prbbalcrd

In the last month, did you have problems
with balance or coordination?

hc6multifall

Since {LAST INT MONTH AND
YEAR} have you fallen down more than
one time?

hc6brokebon1

Since the time of the last interview in
{LAST INT MONTH AND YEAR},

41

Perceived
Severity

Fall risk

has a doctor told you that you had a
broken or fractured hip?

ch6chstndsec
ch62chstrslt
ba6ftdmreslt
ba6ftdmsecs

R6 CH13A TIME REPEAT CH
STD SECS
R6 CH12 REPEAT CHAIR STAND
RSLTS
R6 BA11 FULL TANDEM STAND
RESULT
R6 BA12A SECS HLD FULL TANDM
STD

ss6loenlmtat

In the last month, did your low energy or
exhaustion ever limit your activities?

ss6lowenergy

In the last month, did you have low
energy or were you easily exhausted?

hw6lst10pnds

Have you lost 10 or more pounds in the
last 12 months?

pa6vigoractv

In the last month, did you ever spend
time on vigorous activities that increased
your heart rate and made you breathe
harder? This includes things like
working out, swimming, running or
biking, or playing a sport

pa6evrgowalk

In the last month, did you ever go
walking for exercise?

gr6grp1rdng

Variables used to record the grip
strength and the walking speed over two
trials

Frailty

gr6grp2rdng
wa6wlkc1rslt
wa6wlkc2rslt

Assistance with
doctor

mc6tpersevr3
mc6tpersevr4
mc6tpersevr5
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During those visits in the last year, did
the person from the place where you live
ever:

[c] remind you about things you wanted
to ask or tell the doctor?
[d] ask or tell the doctor things for you?
[e] help you understand what the doctor
was saying?
Perceived
Barriers
Insurance Plans

Ability to perform
tasks

ip6covmedcad

Are you currently covered by or enrolled
in a Medicare Prescription Drug plan,
also called Part D?

ip6otdrugcov

Do you have prescription drug coverage
through a current or former employer or
some other way?

ip6cmedicaid

Are you now covered by Medicaid?

ip6covtricar

Are you now covered by TRICARE?

wb6agrwstmt1

For these last few statements, please tell
me if you agree a lot, a little, or not at
all.

wb6agrwstmt2
wb6agrwstmt3

a. Other people determine most of what I
can and cannot do.
b. When I really want to do something, I
usually find a way to do it.
c. I have an easy time adjusting to
change.

Self- efficacy

Use of technology
for health
purposes

te6intrntmd1
te6intrntmd2
te6intrntmd3

In the last year, have you gone on the
Internet or online to:
a. contact any of {your/his/her} medical
providers?
b. handle Medicare or other health
insurance matters?
c. get information about {your/his/her}
health conditions?
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Cues to action

Difficulty in
swallowing

ss6probchswl

In the last month, did you have problems
with chewing or swallowing that caused
difficulty when you ate?

Regular visits to
doctor

mc6regdoclyr

Have you seen your regular doctor/ a
doctor} within the last year? That is,
since {MONTH AND YEAR 12
MONTHS PRIOR TO TODAY’S
DATE}.
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Table 2: Questions in the NHATS Medication Module
Variable
name
MA1

Variable
detail
ma6attutude1
ma6attitude2
ma6attitude3
ma6attitude4
ma6attitude5
ma6attitude6
ma6attitude7
ma6attitude8

MA2

ma6medsnum

MA3

ma6piilsmax

Variable question

Choice given for the question

You feel that you are taking large
number of medications.
You have a good understanding of
the reasons you are taking each of
your medication.
You feel that you may be taking one
or more medicines that you no longer
need.
If your doctor said it was possible,
you would be willing to stop one or
more of your regular medicines.
You get stressed whenever changes
are made to your medicines.
You believe that all your medicines
are necessary.
You would like to reduce the number
of medicines you are taking.
You would be reluctant to stop a
medicine that you have been taking
for a long time.
About how many different regular
medicines do you take?

The options to choose from were
Strongly agree, Agree, Disagree,
Strongly Disagree/Refused/Don’t
know.

What is the MAXIMUM number of
pills that you would be comfortable
taking daily?
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The options given wereNone, 1-2, 3-5, 6-10, 11-15, 1620, more than 20/Refused/Don’t
know
The options given arePicture A, Picture B, Picture C,
Picture D, Picture E, Picture
F/Refused/ Don’t know.

Table 3: Characteristics of the study population

Respondent
Characteristics

Age
65-74 years
75-84 years
85 years and above
Sex
Men
Women
Race
White NonHispanics
Black NonHispanics
Others
Region
Northeast region
Midwest region
South region
West region
Medication
Burden
0-2 medications
3-10 medications
more than 10
medications
Overall health
Excellent/very
good
Good
Fair/poor
Number of
chronic conditions
0-2
3-4
5-8
Fall risk
High
Moderate
Low
Frailty
Frail

Total

I would like to reduce the number
of medications I am taking

p-value

Unweighted
N (%)

Weighted
(%)

Unweighted
N (%)

Weighted N (%)

149 (26.85%)
238 (42.88%)
168 (30.27%)

41.66%
38.63%
19.71%

95 (28.27%)
146 (43.45%)
95 (28.27%)

836,219 (26.74%)
775,428 (24.79%)
354,421 (11.33%)

0.55

72 (12.97%)
483 (87.03%)

11.82%
88.18%

43 (12.80%)
293 (87.20%)

226,866 (7.25%)
1,739,202 (55.61%)

0.81

405 (72.97%)

81.20%

253 (75.30%)

1,603,484 (51.27%)

0.97

88 (15.86%)

5.91%

48 (14.29%)

113,292 (3.62%)

62 (11.17%)

12.89%

35 (10.42%)

249,292 (7.97%)

97 (17.48%)
126 (22.70%)
218 (39.28%)
114 (20.54%)

17.62%
23.58%
36.84%
21.96%

60 (17.86%)
81 (24.11%)
127 (37.80%)
68 (20.24%)

343,255 (10.97%)
504,359 (16.13%)
719,190 (22.99%)
399,265 (12.77%)

0.62

88 (16.03%)
374 (68.12%)
87 (15.85%)

18.91%
66.16%
14.92%

35 (10.51%)
225 (67.57%)
73 (21.92%)

241,552 (7.81%)
1,301,561 (42.08%)
409,197 (13.23%)

<.0001

171 (30.87%)

34.76%

86 (25.60%)

549,026 (17.58%)

.001

217 (39.17%)
166 (29.96%)

39.81%
25.43%

139 (41.37%)
111 (33.04%)

880,337 (28.19%)
536,705 (17.18%)

272 (49.01%)
234 (42.16%)
49 (8.83%)

56.49%
37.70%
5.81%

157 (46.73%)
142 (42.26%)
37 (11.01%)

1,044,203 (33.38%)
783,212 (25.04%)
138,653 (4.43%)

0.13

75 (15.46%)
72 (14.85%)
338 (69.69%)

13.13%
11.90%
74.97%

50 (17.30%)
50 (17.30%)
189 (65.40%)

252,564 (9.06%)
243,515 (8.73%)
1,231,048 (44.15%)

0.04

51 (9.19%)

8.46%

32 (9.52%)

179,081 (5.73%)

0.83
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Pre-frail
Robust
Assistance with
doctor
Needed
Not needed
Insurance
Yes
no
Ability to perform
tasks
Low
High
Use of technology
for health
purposes
Yes
No
Difficulty in
swallowing
Yes
No
Regular visits to
doctor
Yes
No

410 (73.87%)
94 (16.94%)

73.95%
17.60%

249 (74.11%)
55 (16.37%)

1,447,146 (46.27%)
339,841 (10.87%)

195 (35.14%)
360 (64.86%)

30.75%
69.25%

116 (34.52%)
220 (65.48%)

607,873 (19.43%)
1,358,195 (43.42%)

0.93

516 (92.97%)
39 (7.03%)

93.22%
6.78%

309 (91.96%)
27 (8.04%)

1,825,074 (58.35%)
140,994 (4.51%)

0.68

426 (86.76%)
65 (13.24%)

87.77%
12.23%

261 (85.02%)
46 (14.98%)

1,588,304 (56.34%)
249,013 (8.83%)

0.32

123 (22.16%)
432 (77.84%)

28.54%
71.46%

78 (23.21%)
258 (76.79%)

556,392 (17.79%)
1,409,676 (45.07%)

0.91

67 (12.09%)
487 (87.91%)

10.83%
89.17%

46 (13.69%)
290 (86.31%)

238,164 (7.62%)
1,727,904 (55.28%)

0.24

529 (95.66%)
24 (4.34%)

95.22%
4.78%

320 (95.52%)
15 (4.48%)

1,872,176 (60.21%)
83,101 (2.67%)

0.56
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Table 4: Association between willingness towards deprescribing and patient characteristics
Patient Characteristic
Age
65-74 years
75-84 years
85 years and above
Sex
Men
Women
Race
White Non-Hispanics
Black Non-Hispanics
Others
Region
Northeast region
Midwest region
South region
West region
Medication Burden
0-2 medications
3-10 medications
more than 10 medications
Overall health
Excellent/very good
Good
Fair/poor
Number of chronic conditions
0-2
3-4
5-8
Fall risk
Low
High
Moderate
Frailty
Robust
Frail
Pre-frail
Assistance with doctor
Needed
Not needed
Insurance

I would like to reduce the
number of medicines I am
taking, OR (95% CI)

p-value

[Reference]
0.80 (0.44-1.45)
0.45 (0.23-0.89)

0.46
0.02

[Reference]
0.95 (0.43-2.12)

0.91

[Reference]
0.88 (0.35-2.17)
1.63 (0.65-4.10)

0.77
0.29

[Reference]
1.53 (0.70-3.35)
0.75 (0.39-1.44)
1.09 (0.47-2.49)

0.29
0.38
0.84

[Reference]
2.42 (1.20-4.86)
14.66 (5.36-40.11)

0.01
<.0001

[Reference]
1.56 (0.85-2.89)
1.23 (0.56-2.69)

0.15
0.61

[Reference]
0.85 (0.46-1.56)
0.88 (0.30-2.56)

0.59
0.81

[Reference]
1.62 (0.66-3.97)
1.67 (0.84-3.31)

0.29
0.14

[Reference]
0.62 (0.16-2.49)
0.73 (0.34-1.56)

0.50
0.41

[Reference]
0.80 (0.45-1.41)

0.43
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Yes
no
Ability to perform tasks
Low
High
Use of technology for health
purposes
Yes
No
Difficulty in swallowing
Yes
No
Regular visits to doctor
Yes
No

[Reference]
1.35 (0.63-2.88)

0.43

[Reference]
1.41 (0.52-3.82)

0.49

[Reference]
0.98 (0.49-1.99)

0.96

[Reference]
1.31 (0.58-2.97)

0.51

[Reference]
0.81 (0.25-2.67)

0.73
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